Verona Pharma plc Verona Pharma Plc : 1st Quarter Results
09 March 2018 - 12:38AM
UK Regulatory
TIDMVRP TIDMVRP
LONDON, March 08, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP)
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical
company focused on developing and commercializing innovative therapies
for respiratory diseases, announces that, on March 7, 2018, Dr.
Jan-Anders Karlsson, Chief Executive Officer of the Company, purchased
3,250 ordinary shares of 5 pence each in the Company (the "Ordinary
Shares") at a price of 148.64 pence per Ordinary Share. Following the
acquisition, Dr. Karlsson will have an interest in the Company of 92,400
Ordinary Shares, representing 0.09% of the Company's issued share
capital.
The notification set out below is provided in accordance with the
requirements of the EU Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Jan-Anders Karlsson
2 Reason for the notification
Chief Executive Officer
a) Position/status
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Verona Pharma plc
b) LEI 213800EVI6O6J3TIAL06
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 5 pence each
Identification code GB00BYW2KH80
b) Nature of the transaction Jan-Anders Karlsson purchased 3,250
Ordinary Shares
c) Price(s) and volume(s) Price(s) Volume(s)
148.64 pence per 3,250 Ordinary
Ordinary Share Shares
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 7 March 2018
f) Place of the transaction London Stock Exchange, AIM
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44 (0) 20 7710 7600
and UK Broker) SNELVeronaPharma@stifel.com
Stewart Wallace / Jonathan Senior / Ben Maddison
This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: Verona Pharma plc via Globenewswire
http://www.veronapharma.com/
(END) Dow Jones Newswires
March 08, 2018 08:38 ET (13:38 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Verona Pharma Plc (London Stock Exchange): 0 recent articles
More Verona Pharma News Articles